← Human Trials & Peer-Reviewed Studies
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study.
Plain-language guide to PMID 23208074 (2013): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 36,282 women.
Key Facts
- PMID
- 23208074
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2013
- Study type
- Randomized Controlled Trial
- Authors
- Prentice RL et al. (14 authors)
- DOI
- 10.1007/s00198-012-2224-2
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.
Who Took Part
According to the abstract, 36,282 women were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
WHI calcium and vitamin D randomized clinical trial (CT) data through the end of the intervention period were further analyzed with emphasis on treatment effects in relation to duration of supplementation, and these data were contrasted and combined with corresponding data from the WHI prospective observational study (OS).
How the Study Was Run
The design is described as randomized, double-blind and placebo-controlled.
The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.
Blinding on both sides kept the women and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
What Was Measured
Topics PubMed links to this paper include Bone Density Conservation Agents, Calcium Carbonate, Cardiovascular Diseases, Cholecalciferol, Dietary Supplements, Hip Fractures and Neoplasms.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 36,282 women.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.